Heron Therapeutics vs Precigen
HRTX and PGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HRTX and PGEN compare
Precigen is the larger company, worth 28 times as much as Heron Therapeutics ($1.6B against $58.9M).
Precigen keeps more of each dollar of sales as profit, with a net margin of 15.6% compared with −14.5% at Heron Therapeutics.
Heron Therapeutics scores higher on the StockData Score (8 against 6 for Precigen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HRTX | PGEN |
|---|---|---|
| Size and price | ||
| Market cap | $58.9M | $1.6B |
| Share price | $0.310 | $4.54 |
| Change, 1 year | −72.0% | 12.9% |
| Change, 5 years | −96.9% | 20.7% |
| Beta (5Y) | 1.79 | 1.63 |
| Employees | 128 | 20 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 | 4 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 114× |
| P/S | 0.4× (better) | 10.4× |
| P/B | 12.0× (better) | 19.4× |
| EV/EBITDA | – | 43.8× |
| FCF yield | −24.4% | −4.6% (better) |
| Fair value | – | $1.34 |
| Margin of safety | – | −239% |
| Growth | ||
| Revenue growth (TTM) | −4.4% | – |
| Revenue growth, 5Y average | 11.8% (better) | −21.3% |
| Profitability | ||
| Gross margin | 71.5% | – |
| Operating margin | −5.7% | 21.4% (better) |
| Net margin | −14.5% | 15.6% (better) |
| FCF margin | −9.7% (better) | −47.4% |
| Return on equity | −218% | 38.8% (better) |
| Return on invested capital | – | 147% |
| Financial health | ||
| Debt / equity | 0.00 | 1.12 (better) |
| Net debt / EBITDA | – | 1.14 |
| Interest coverage | – | 2.8× |
| Current ratio | 2.33 | 5.58 (better) |
| Altman Z-score | −10.60 | −5.48 (better) |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 70.4% | 39.2% |
| Held by insiders | 21.6% | 44.9% |
| Insider net buying, 12 months | – | −$32.5M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 22.8% | 22.8% |
Go deeper
- HRTX stock overview
- HRTX income statement
- HRTX valuation and score
- PGEN stock overview
- PGEN income statement
- PGEN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.